We are almost there ...
Despite legal struggles, investors’ confidence remains strong in the pharma giant.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
A gung-ho attitude to the market hinges on rate cut expectations, but the risk of tapering earnings growth spoiling the party is a very real prospect.